181 related articles for article (PubMed ID: 31897759)
1. No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis.
Ferrieres L; Degboe Y; Laroche M; Constantin A; Ruyssen-Witrand A
Arch Osteoporos; 2020 Jan; 15(1):10. PubMed ID: 31897759
[TBL] [Abstract][Full Text] [Related]
2. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
3. Comments to "No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis".
Yang S; Dong Z; Kan B
Osteoporos Int; 2023 Mar; 34(3):617-623. PubMed ID: 36550210
[No Abstract] [Full Text] [Related]
4. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
5. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
Dempster DW; Zhou H; Recker RR; Brown JP; Recknor CP; Lewiecki EM; Miller PD; Rao SD; Kendler DL; Lindsay R; Krege JH; Alam J; Taylor KA; Janos B; Ruff VA
J Clin Endocrinol Metab; 2016 Apr; 101(4):1353-63. PubMed ID: 26859106
[TBL] [Abstract][Full Text] [Related]
6. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
Wu J; Zhang Q; Yan G; Jin X
J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
[TBL] [Abstract][Full Text] [Related]
7. Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.
Ho WC; Chang CC; Wu WT; Lee RP; Yao TK; Peng CH; Yeh KT
Curr Rheumatol Rep; 2024 May; 26(5):188-195. PubMed ID: 38372871
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
9. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
Quemerais-Durieu MA; Kerlan V; Chabre O
Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
[TBL] [Abstract][Full Text] [Related]
11. Bone biology, signaling pathways, and therapeutic targets for osteoporosis.
Iñiguez-Ariza NM; Clarke BL
Maturitas; 2015 Oct; 82(2):245-55. PubMed ID: 26255682
[TBL] [Abstract][Full Text] [Related]
12. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.
Yuan F; Peng W; Yang C; Zheng J
Int J Surg; 2019 Jun; 66():1-11. PubMed ID: 30890377
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
17. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
[TBL] [Abstract][Full Text] [Related]
18. Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials.
Catton B; Surangiwala S; Towheed T
Int J Rheum Dis; 2021 Jul; 24(7):869-879. PubMed ID: 33793076
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
Valverde P
Curr Med Chem; 2008; 15(3):284-304. PubMed ID: 18288984
[TBL] [Abstract][Full Text] [Related]
20. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
Fan G; Zhao Q; Lu P; Chen H; Tan W; Guo W; Liu C; Liu J
Medicine (Baltimore); 2020 Apr; 99(15):e18964. PubMed ID: 32282692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
